• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nycomed shares rise on Altana rumors

Article

The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already

The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already jointly marketing an ulcer drug, and may be looking for ways to expand their partnership, according to AFX News.

Nycomed has been the subject of merger or acquisition rumors since its proposed merger with U.S. generic drug firm Ivax broke down in 1995 (SCAN 12/13/95). The company said at the time the deal fell apart that it would continue to pursue strategic partnerships. Nycomed executives declined to comment on the Altana rumors.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.